{"id":2310,"date":"2017-09-15T18:00:18","date_gmt":"2017-09-15T12:30:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2310"},"modified":"2025-05-12T14:24:21","modified_gmt":"2025-05-12T08:54:21","slug":"human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","title":{"rendered":"Human Papillomavirus (HPV) Prophylaxis\u2013 Expected to see a steady growth from 2015-2025"},"content":{"rendered":"<p style=\"text-align: justify;\">A total of approximately <strong>7.3 Million<\/strong> people were vaccinated with HPV vaccines in 2016, as per the latest report of <a href=\"https:\/\/www.delveinsight.com\">DelveInsight<\/a>. Human Papillomavirus is a double stranded DNA virus that infects squamous epithelia including the skin and mucosae of the upper respiratory and anogenital tracts. HPV is a group of more than <strong>200<\/strong> related viruses, whose infections are so common that nearly all men and women will get at least one type of HPV at some point in their lives. The number of people getting vaccinated for these infections is estimated to increase in the coming years due to the expected increase in the coverage of HPV vaccines.<\/p>\n<blockquote>\n<p style=\"text-align: justify;\">The <a href=\"https:\/\/www.delveinsight.com\/report-store\/human-papillomavirus-hpv-associated-disorders-market\">HPV Prophylaxis <\/a>market was estimated at <strong>1.98 Billion<\/strong> in 2016 for 7MM\u2019s. Due to proper awareness in the United States, it has a major hold over HPV Prophylaxis market and accounts for <strong>90.5%<\/strong> of the total revenue coming from the 7 major markets (US, Germany, Spain, Italy, France, UK and Japan).<\/p>\n<\/blockquote>\n<p style=\"text-align: justify;\">There were no approved vaccines for HPV prophylaxis till 2006, but after the approval of <strong>Gardasil<\/strong> (Quadrivalent vaccine) in U.S. and <strong>Cervarix<\/strong> (Bivalent vaccine) in Europe, the market scenario has improved. Also, the HPV market had a major setback when Japanese government withdrew its support for vaccines after a report published the side effects that girls had after vaccination. Japan has had a negligible contribution in the recent years to the total HPV market, in comparison to the other 6 major markets.<\/p>\n<p style=\"text-align: justify;\">According to a study published in 2016, if Japan reinstates the governmental recommendation for the vaccine, this would induce a <strong>4.1 % <\/strong>increase in the number of vaccination that the girls would undergo for HPV infections. It is expected that due to higher demand of <strong>Gardasil-9<\/strong> (Merck) and increasing population pool, the market will increase in the coming years. Currently, there are only three approved HPV vaccines in the market and no emerging vaccines are in the pivotal stage of development. DelveInsight believes that there will be a steady growth in HPV prophylaxis market in the forecast period due to increase in vaccination rates and increasing awareness.<\/p>\n<p style=\"text-align: justify;\"><em>Insights by:<\/em><br \/>\n<em>Harshit Saini<\/em><br \/>\n<em>Associate Analyst<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A total of approximately 7.3 Million people were vaccinated with HPV vaccines in 2016, as per the latest report of DelveInsight. Human Papillomavirus is a double stranded DNA virus that infects squamous epithelia including the skin and mucosae of the upper respiratory and anogenital tracts. HPV is a group of more than 200 related viruses, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[17579,1024,1022,1023,1025,1021,17577,395,17578],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-2310","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-gardasil","tag-gardasil-9","tag-hpv-prophylaxis-market","tag-hpv-vaccines","tag-human-papillomavirus","tag-human-papillomavirus-hpv-prophylaxis","tag-human-papillomavirus-market","tag-merck","tag-prophylaxis","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expected to see a steady growth in Human Papillomavirus Prophylaxis<\/title>\n<meta name=\"description\" content=\"The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM\u2019s. A total of approximately 7.3 Million people were vaccinated with HPV vaccines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expected to see a steady growth in Human Papillomavirus Prophylaxis\" \/>\n<meta property=\"og:description\" content=\"The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM\u2019s. A total of approximately 7.3 Million people were vaccinated with HPV vaccines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-15T12:30:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T08:54:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"892\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Expected to see a steady growth in Human Papillomavirus Prophylaxis","description":"The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM\u2019s. A total of approximately 7.3 Million people were vaccinated with HPV vaccines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","og_locale":"en_US","og_type":"article","og_title":"Expected to see a steady growth in Human Papillomavirus Prophylaxis","og_description":"The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM\u2019s. A total of approximately 7.3 Million people were vaccinated with HPV vaccines.","og_url":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-15T12:30:18+00:00","article_modified_time":"2025-05-12T08:54:21+00:00","og_image":[{"width":900,"height":892,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","url":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025","name":"Expected to see a steady growth in Human Papillomavirus Prophylaxis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16.jpg","datePublished":"2017-09-15T12:30:18+00:00","dateModified":"2025-05-12T08:54:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM\u2019s. A total of approximately 7.3 Million people were vaccinated with HPV vaccines.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/human-papillomavirus-hpv-prophylaxis-expected-to-see-a-steady-growth-from-2015-2025#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16.jpg","width":900,"height":892},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/human-papillomavirus-type-16-300x297.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gardasil<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gardasil-9<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">HPV Prophylaxis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">HPV vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Human Papillomavirus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Human Papillomavirus (HPV) Prophylaxis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Human Papillomavirus Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Prophylaxis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Gardasil<\/span>","<span class=\"advgb-post-tax-term\">Gardasil-9<\/span>","<span class=\"advgb-post-tax-term\">HPV Prophylaxis market<\/span>","<span class=\"advgb-post-tax-term\">HPV vaccines<\/span>","<span class=\"advgb-post-tax-term\">Human Papillomavirus<\/span>","<span class=\"advgb-post-tax-term\">Human Papillomavirus (HPV) Prophylaxis<\/span>","<span class=\"advgb-post-tax-term\">Human Papillomavirus Market<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Prophylaxis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Sep 15, 2017","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Sep 15, 2017 6:00 pm","modified":"Updated on May 12, 2025 2:24 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2310"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2310\/revisions"}],"predecessor-version":[{"id":32050,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2310\/revisions\/32050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2312"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2310"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2310"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}